Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BG-75098 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on BG-75098, a putative Cdk2 degrader (Nov 2025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BG-75098 | BG75098|BG 75098 | Limited information is currently available on BG-75098, a putative Cdk2 degrader (Nov 2025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07226349 | Phase I | BG-75098 + BGB-43395 + Fulvestrant BG-75098 | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | Not yet recruiting | USA | 0 |